Invivyd Inc. reports Q3 net product revenue of $13.1 million

Reuters

2025/11/06

Invivyd Inc. reports Q3 net product revenue of $13.1 million

Invivyd Inc. reported net product revenue of $13.1 million for PEMGARDA (pemivibart) in the third quarter of 2025, reflecting a 41% year-over-year increase and 11% growth compared to the previous quarter. The company ended the third quarter of 2025 with $85.0 million in cash and cash equivalents, and over $100 million by the end of October 2025. Invivyd completed a public offering in August 2025, raising approximately $57.5 million in gross proceeds, and generated an additional $29.8 million through an at-the-market offering facility in October 2025. Business developments during the period included the U.S. IND clearance and FDA alignment for the VYD2311 pivotal clinical program, expanded commercial activity for PEMGARDA among healthcare providers treating immunocompromised patients, new leadership appointments, and the formation of the SPEAR Study Group to assess monoclonal antibody therapy for Long COVID and COVID-19 Post-Vaccination Syndrome.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Invivyd Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-268057), on November 06, 2025, and is solely responsible for the information contained therein.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2581062092"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2581062092\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2581062092?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-06 20:11","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2581062092","market":"nz","top_or_hot":-1,"title":"Invivyd Inc. reports Q3 net product revenue of $13.1 million","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Invivyd Inc. reports Q3 net product revenue of $13.1 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Invivyd Inc. reported net product revenue of $13.1 million for PEMGARDA (pemivibart) in the third quarter of 2025, reflecting a 41% year-over-year increase and 11% growth compared to the previous quarter. The company ended the third quarter of 2025 with $85.0 million in cash and cash equivalents, and over $100 million by the end of October 2025. Invivyd completed a public offering in August 2025, raising approximately $57.5 million in gross proceeds, and generated an additional $29.8 million through an at-the-market offering facility in October 2025. Business developments during the period included the U.S. IND clearance and FDA alignment for the VYD2311 pivotal clinical program, expanded commercial activity for PEMGARDA among healthcare providers treating immunocompromised patients, new leadership appointments, and the formation of the SPEAR Study Group to assess monoclonal antibody therapy for Long COVID and COVID-19 Post-Vaccination Syndrome.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Invivyd Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-268057), on November 06, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Invivyd Inc. reports Q3 net product revenue of $13.1 million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInvivyd Inc. reports Q3 net product revenue of $13.1 million\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-11-06 20:11</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Invivyd Inc. reports Q3 net product revenue of $13.1 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Invivyd Inc. reported net product revenue of $13.1 million for PEMGARDA (pemivibart) in the third quarter of 2025, reflecting a 41% year-over-year increase and 11% growth compared to the previous quarter. The company ended the third quarter of 2025 with $85.0 million in cash and cash equivalents, and over $100 million by the end of October 2025. Invivyd completed a public offering in August 2025, raising approximately $57.5 million in gross proceeds, and generated an additional $29.8 million through an at-the-market offering facility in October 2025. Business developments during the period included the U.S. IND clearance and FDA alignment for the VYD2311 pivotal clinical program, expanded commercial activity for PEMGARDA among healthcare providers treating immunocompromised patients, new leadership appointments, and the formation of the SPEAR Study Group to assess monoclonal antibody therapy for Long COVID and COVID-19 Post-Vaccination Syndrome.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Invivyd Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-268057), on November 06, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IVVD","symbol_name":"Invivyd, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nNDLbLZKJp:1","article_id":"2581062092","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2581062092","pubTimestamp":1762431084,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Invivyd Inc. reported net product revenue of $13.1 million for PEMGARDA  in the third quarter of 2025, reflecting a 41% year-over-year increase and 11% growth compared to the previous quarter. The company ended the third quarter of 2025 with $85.0 million in cash and cash equivalents, and over $100 million by the end of October 2025. Invivyd completed a public offering in August 2025, raising approximately $57.5 million in gross proceeds, and generated an additional $29.8 million through an at-the-market offering facility in October 2025. Business developments during the period included the U.S. IND clearance and FDA alignment for the VYD2311 pivotal clinical program, expanded commercial activity for PEMGARDA among healthcare providers treating immunocompromised patients, new leadership appointments, and the formation of the SPEAR Study Group to assess monoclonal antibody therapy for Long COVID and COVID-19 Post-Vaccination Syndrome.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IVVD":"Invivyd, Inc.","BK4539":"次新股","BK4139":"生物科技"},"translate_title":"Invivyd Inc.报告第三季度产品净收入为1310万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IVVD":0.9},"content_text":"Invivyd Inc. reports Q3 net product revenue of $13.1 million\n    \n\n        Invivyd Inc. reported net product revenue of $13.1 million for PEMGARDA (pemivibart) in the third quarter of 2025, reflecting a 41% year-over-year increase and 11% growth compared to the previous quarter. The company ended the third quarter of 2025 with $85.0 million in cash and cash equivalents, and over $100 million by the end of October 2025. Invivyd completed a public offering in August 2025, raising approximately $57.5 million in gross proceeds, and generated an additional $29.8 million through an at-the-market offering facility in October 2025. Business developments during the period included the U.S. IND clearance and FDA alignment for the VYD2311 pivotal clinical program, expanded commercial activity for PEMGARDA among healthcare providers treating immunocompromised patients, new leadership appointments, and the formation of the SPEAR Study Group to assess monoclonal antibody therapy for Long COVID and COVID-19 Post-Vaccination Syndrome.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Invivyd Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-268057), on November 06, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}